Share

We are pleased to announce the release of the EORTC 2023 Annual Report

The EORTC Annual Report represents a valuable opportunity to celebrate our recent milestones and reaffirm our mission and goals. Whether you have been familiar with EORTC for many years or have just joined our network, you will find insightful information that provides a comprehensive overview of our work at EORTC.

This year’s edition includes a new chapter dedicated to the EORTC Scientific Strategy, outlining the priorities for our research programmes aimed at enhancing survival and quality of life for cancer patients. This strategic focus is crucial as we navigate the evolving landscape of clinical cancer research. For the first time, we also highlight the contributions of young and early career investigators, showcasing the next generation of researchers committed to advancing cancer treatment and care. Additionally, we feature dedicated chapters on the two EORTC councils: the newly established Older Adults Council (OAC) and the Radiation Oncology Scientific Council (ROSC).

EORTC’s continuous progress is made possible by its extensive network, which in 2023 reached over 3,800 members from diverse disciplines across 58 countries. Our commitment to methodological, scientific, and regulatory advancements in oncology remains strong, as does our dedication to education in clinical research-related science. With 22,700 patients in follow-up and more than 215,000 patients in our databases, EORTC remains the leading independent non-profit clinical cancer research organisation in Europe.

We extend our sincere gratitude to all the people who support, collaborate, and believe in the mission of EORTC to improve the survival and quality of life for cancer patients worldwide. Explore the full EORTC Annual Report 2023 to learn more.

Back to news list

Related News

  • IMMUcan has completed patient enrolment

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

  • Spotlight on ENA 2024 News

  • Do regulations and policies undermine the social value of independent academic research?

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival

  • New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024

  • Late Breaking Results from the EORTC 1333/PEACE III phase III trial